- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2013
- Public Summary Document (PSD) March 2013 PBAC Meeting - PDF
Eculizumab – March 2013
Eculizumab, concentrated solution for IV infusion, 300 mg in 30 mL, Soliris®
Last updated
8 November 2023